Hermanowicz Stefan, Hermanowicz Neal
a Department of Biochemistry and Molecular Biology , School of Health Sciences, University of Iceland , Reykjavik , Iceland.
b Department of Neurology , School of Health Sciences, University of California , Irvine , CA , USA.
Expert Rev Neurother. 2016 Jun;16(6):625-33. doi: 10.1586/14737175.2016.1158102.
Parkinson's disease psychosis (PDP) is a common and often very disturbing component of Parkinson's disease (PD). PDP consists of hallucinations that are mainly visual and delusions that are often of a paranoid nature. These symptoms can be the most troubling and disruptive of all the manifestations of Parkinson's disease. Current treatment methods include the reduction of anti-Parkinson's medications, a strategy that may worsen the motor problems the medications are prescribed to alleviate, and the introduction of selected antipsychotic medications that carry with them the potential for troubling side effects and serious consequences. Pimavanserin has been developed and studied in clinical trials to specifically address Parkinson's disease psychosis and has been submitted to the U.S. Food and Drug Administration for its approval for this purpose. If this is granted, we believe the evidence of Pimavanserin efficacy, safety and tolerability will position this medication as the first choice for treatment of Parkinson's disease psychosis.
帕金森病精神病（PDP）是帕金森病（PD）常见且往往令人极为困扰的一个组成部分。PDP包括主要为视幻觉以及常常具有偏执性质的妄想。这些症状可能是帕金森病所有表现中最令人烦恼和具有破坏性的。当前的治疗方法包括减少抗帕金森病药物用量，这一策略可能会使药物原本旨在缓解的运动问题恶化，以及引入某些抗精神病药物，而这些药物可能会带来令人烦恼的副作用和严重后果。匹莫范色林已研发并在临床试验中进行研究，专门用于治疗帕金森病精神病，并且已提交给美国食品药品监督管理局以获得此项用途的批准。如果获批，我们相信匹莫范色林在疗效、安全性和耐受性方面的证据将使其成为治疗帕金森病精神病的首选药物。
